drugset / Trial / NCT03169127

Clinical Pharmacogenetic of Ibuprofen After Lower Third Molar Surgeries

NCT03169127

NaSingle-groupOpen-labelSupportive care

Summary

The present clinical trial randomized will be to assess the link between the different haplotypes of CYP2C8 and CYP2C9 genes and the clinical efficacy of ibuprofen after lower third molar extractions. Onset, duration of postoperative analgesia, duration of anesthetic action on soft tissues, intraoperative bleeding, hemodynamic parameters, postoperative mouth opening and wound healing at the 7th postoperative day were evaluated. For this purpose, 200 healthy volunteers underwent removal of one lower third molar, under local anesthesia with articaine 4% (1:200,000 adrenaline) will be genotyped and phenotyped for these genes and their postoperative records with all data collected will be compared with the haplotypes found in the Brazilian population.

Timeline

Start
2016-04-01
Primary completion
2018-07-30
Completion
2020-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibuprofen Small molecule 600 mg